<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02173704</url>
  </required_header>
  <id_info>
    <org_study_id>205249</org_study_id>
    <secondary_id>V72_60</secondary_id>
    <nct_id>NCT02173704</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants of 2 Months of Age and Older, in Taiwan.</brief_title>
  <official_title>A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Routine Vaccines to Healthy Infants in Taiwan.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis Vaccines</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assess the safety and immunogenicity of a 3-dose schedule (at 2, 4, 6 months) of Novartis
      Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly
      administered with routine vaccines in healthy infants in Taiwan.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity: percentage of subjects with SBA titer higher than or equal to 1:5</measure>
    <time_frame>1 month following the third Vaccination</time_frame>
    <description>To demonstrate the sufficiency of the immune response to rMenB+OMV NZ vaccine, when given concomitantly with routine vaccines (i.e DTaP-IPV-Hib, HepB and PCV-13) to healthy infants at 2, 4, 6 months of age, as measured by percentage of subjects with serum bactericidal activity (SBA) titer ≥ 1:5 against the indicator strains H44/76, 5/99 and NZ98/254 at 1 month after the third vaccination (at 7 months of age).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: assess percentage and numbers of subjects with local and systemic adverse events</measure>
    <time_frame>Until Day 7 post-each vaccination</time_frame>
    <description>Assess the safety of a 3-dose schedule (at 2, 4, 6 months) of Novartis Meningococcal B recombinant vaccine followed by a booster at 12 months when concomitantly administered with routine vaccines in healthy infants in Taiwan.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety: percentage of subjects with SAEs, medically attended AEs and AEs leading to study withdrawal</measure>
    <time_frame>Until study end (at 13 months of age)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects with SBA titer higher than or equal to 1:5</measure>
    <time_frame>1 month following the booster</time_frame>
    <description>- To demonstrate the sufficiency of the immune response to a booster dose of rMenB+OMV NZ vaccine when given concomitantly with routine vaccines (i.e. MMR and varicella) to healthy toddlers at 12 months of age that were previously primed with 3-doses of rMenB+OMV NZ, as measured by percentage of subjects with SBA titer ≥ 1:5 against the indicator strains H44/76, 5/99 and NZ98/254 at 1 month after the booster dose (at 13 months of age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBA GMTs</measure>
    <time_frame>Baseline (2 months of age), 1 month after the third vaccination (7 months of age), prior to the booster vaccination (12 months of age), 1 month after the booster vaccination (13 months of age)</time_frame>
    <description>To assess bactericidal antibodies against meningococcal B in healthy infants receiving rMenB+OMV NZ concomitantly with routine vaccines (Group A) or routine vaccines alone (Group B) at 2, 4, 6 and 12 months of age, as measured by SBA geometric mean titers (GMTs) and percentage of subjects with SBA titer ≥ 1:5 against indicator strains H44/76, 5/99, NZ98/254 and strain M10713 at baseline (2 months of age), 1 month after the third vaccination (7 months of age), prior to the booster dose (12 months of age) and at 1 month after the booster dose (13 months of age).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SBA GMRs</measure>
    <time_frame>1 month after the third vaccination (7 months of age), prior to the booster vaccination (12 months of age), 1 month after the booster vaccination (13 months of age) to Baseline (2 months of age)</time_frame>
    <description>To assess bactericidal antibodies against meningococcal B in healthy infants receiving rMenB+OMV NZ concomitantly with routine vaccines (Group A) or routine vaccines alone (Group B) at 2, 4, 6 and 12 months of age, as measured by SBA geometric mean ratios between post and pre-vaccination (baseline) titers (GMRs) and percentage of subjects with SBA titer ≥ 1:5 against indicator strains H44/76, 5/99, NZ98/254 and strain M10713 at baseline (2 months of age), 1 month after the third vaccination (7 months of age), prior to the booster dose (12 months of age) and at 1 month after the booster dose (13 months of age).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of subjects with SBA titers ≥ 1:8</measure>
    <time_frame>Baseline &amp; one month after the third Vaccination, at 12 months of age (prior to the booster dose) and at 13 months of age (one</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">225</enrollment>
  <condition>Meningococcal Disease</condition>
  <arm_group>
    <arm_group_label>Bexsero + Routine Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects received three doses of Bexsero® vaccine at 2, 4, 6 months followed by a booster dose at 12 months, concomitantly administered with routine vaccines (i.e. combined Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® at 6 months of age; Priorix® and Varilrix® at 12 months of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Routine Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects received routine vaccines Infanrix-IPV + Hib® and Prevenar-13® at 2, 4, 6 months of age; Engerix-B® vaccine at 6 months; Priorix® and Varilrix® vaccines at 12 months of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Bexsero®</intervention_name>
    <description>Four doses administered in the anterolateral area of the right or left thigh.</description>
    <arm_group_label>Bexsero + Routine Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Routine vaccines</intervention_name>
    <description>Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.</description>
    <arm_group_label>Routine Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. healthy 2-month old infants (55-89 days, inclusive), who were born after full term
             pregnancy with an estimated gestational age ≥ 37 weeks and a birth weight ≥ 2.5 kg;

          2. for whom a parent/legal guardian has given written informed consent after the nature
             of the study has been explained;

          3. available for all the visits scheduled in the study;

          4. in good health as determined by medical history, physical examination and clinical
             judgment of the investigator.

        Exclusion Criteria:

          1. History of any meningococcal vaccine administration;

          2. Prior vaccination with any Diphtheria, Tetanus, Pertussis (acellular or whole cell),
             Polio (either Inactivated or Oral), Haemophilus influenzae type b (Hib), Pneumococcal,
             MMR or varicella antigens;

          3. Previous ascertained or suspected disease caused by N. meningitidis;

          4. Household contact with and/or intimate exposure to an individual with laboratory
             confirmed N. meningitidis;

          5. History of severe allergic reaction after previous vaccinations or hypersensitivity to
             any vaccine component;

          6. Significant acute or chronic infection within the previous 7 days or body temperature
             higher or equal to 38C degrees within the previous day;

          7. Antibiotics within 6 days prior to enrollment;

          8. Any serious chronic or progressive disease according to the judgment of the
             investigator (e.g., neoplasm, insulin dependent diabetes mellitus Type I, cardiac
             disease, hepatic disease, progressive neurological disease or seizure, either
             associated with fever or as part of an underlying neurological disorder or syndrome,
             autoimmune disease, HIV infection or AIDS, or blood dyscrasias or diathesis, signs of
             cardiac or renal failure or severe malnutrition);

          9. Known or suspected impairment/alteration of the immune system, immunosuppressive
             therapy, use of systemic corticosteroids or chronic use of inhaled high-potency
             corticosteroids since birth;

         10. Receipt of blood, blood products and/or plasma derivatives or any parenteral
             immunoglobulin preparation;

         11. Receipt of, or intent to immunize with any other vaccine(s) (with the exception of
             rotavirus vaccine, influenza vaccine and second HepB vaccine), within 28 days prior
             and throughout the study period. Furthermore, subjects must have received HepB vaccine
             preferably at 0, 1 month of age, with the second dose at least 14 days prior to study
             vaccination. Influenza vaccine should be administered at least 14 days before or 14
             days after study vaccination; Rotavirus vaccine may be administered during the study
             as per local practice.

         12. Participation in another clinical trial since birth or planned for during study;

         13. Family members and household members of research staff;

         14. Any condition which, in the opinion of the investigator, might interfere with the
             evaluation of the study objectives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Days</minimum_age>
    <maximum_age>89 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>10048</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Taipei</city>
        <zip>10449</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2014</study_first_posted>
  <disposition_first_submitted>January 4, 2016</disposition_first_submitted>
  <disposition_first_submitted_qc>January 4, 2016</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">February 3, 2016</disposition_first_posted>
  <last_update_submitted>December 9, 2016</last_update_submitted>
  <last_update_submitted_qc>December 9, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Meningitis</keyword>
  <keyword>Infants</keyword>
  <keyword>Meningococcal B Recombinant Vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meningococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 20, 2017</submitted>
    <returned>April 4, 2017</returned>
    <submitted>July 28, 2017</submitted>
    <returned>February 14, 2018</returned>
    <submitted>March 16, 2018</submitted>
    <returned>March 16, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

